Based on the promising efficacy, in 2021, the U.S. FDA granted tiragolumab BTD in combination with atezolizumab (Tecentriq) for the first‐line treatment of individuals with metastatic NSCLC whose tumors have PD‐L1 expression ≥50% and no EGFR or ALK genomic tumor aberrations. Here, ALK is linked to neoplasm.